243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.
dc.contributor.author | Delaloge, S | |
dc.contributor.author | Conte, P | |
dc.contributor.author | Im, S | |
dc.contributor.author | Senkus-Konefka, E | |
dc.contributor.author | Xu, B | |
dc.contributor.author | Domchek, S | |
dc.contributor.author | Masuda, N | |
dc.contributor.author | Li, W | |
dc.contributor.author | Tung, N | |
dc.contributor.author | Armstrong, Anne C | |
dc.contributor.author | Wu, W | |
dc.contributor.author | Goessl, C | |
dc.contributor.author | Runswick, S | |
dc.contributor.author | Robson, M | |
dc.date.accessioned | 2017-11-23T21:45:54Z | |
dc.date.available | 2017-11-23T21:45:54Z | |
dc.date.issued | 2017-09 | |
dc.identifier.citation | 243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. 2017, 28(suppl_5): Ann Oncol | en |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.doi | 10.1093/annonc/mdx365.006 | |
dc.identifier.uri | http://hdl.handle.net/10541/620703 | |
dc.language.iso | en | en |
dc.relation.url | http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.006/4108472/243PDOlympiAD-Further-efficacy-outcomes-in | en |
dc.rights | Archived with thanks to Annals of Oncology | en |
dc.title | 243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Breast Cancer Group, Institut Gustave Roussy, Villejuif, France | en |
dc.identifier.journal | Annals of Oncology | en |